Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet

This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of corresponding doses of sitagliptin and China-sourced metformin as individual tablets will be bioequivalent based on assessment of the AUC(0-t) and Cmax, for both sitagliptin and metformin.

Inclusion Criteria:

• Subject is of Chinese descent
• Subject is in good health
• Subject is a non-smoker

Exclusion Criteria:

• Subject has a history of stroke or chronic seizures
• Subject has a history of cancer
• Subject has had major surgery, donated blood or participated in another investigational study within the past 4 weeks